KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Assets: 2018-2024

Historic Other Non-Current Assets for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $1.2 million.

  • Castle Biosciences' Other Non-Current Assets fell 29.98% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 29.98%. This contributed to the annual value of $1.2 million for FY2024, which is 14.72% down from last year.
  • As of FY2024, Castle Biosciences' Other Non-Current Assets stood at $1.2 million, which was down 14.72% from $1.4 million recorded in FY2023.
  • Castle Biosciences' Other Non-Current Assets' 5-year high stood at $1.7 million during FY2021, with a 5-year trough of $1.1 million in FY2022.
  • Over the past 3 years, Castle Biosciences' median Other Non-Current Assets value was $1.2 million (recorded in 2024), while the average stood at $1.3 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 1,037.78% in 2020, then crashed by 35.28% in 2022.
  • Over the past 5 years, Castle Biosciences' Other Non-Current Assets (Yearly) stood at $1.5 million in 2020, then increased by 11.65% to $1.7 million in 2021, then crashed by 35.28% to $1.1 million in 2022, then climbed by 29.73% to $1.4 million in 2023, then fell by 14.72% to $1.2 million in 2024.